Isatuximab + Cemiplimab

Phase 2Recruiting

0 views this week 0 watching⚡ Active🧪Featured in Gene & Cell Therapy Watch

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Natural Killer/T-cell Lymphoma

Conditions

Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma

Trial Timeline

Jun 25, 2021 → Apr 30, 2026

NCT ID

NCT04763616

About Isatuximab + Cemiplimab

Isatuximab + Cemiplimab is a phase 2 stage product being developed by Sanofi for Natural Killer/T-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04763616. Target conditions include Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04763616	Phase 2	Recruiting	Jun 25, 2021	Apr 30, 2026	Natural Killer/T-cell Lymphoma